{
  "success": true,
  "pagesUsed": [
    3,
    9,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    23,
    34,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Screening Window",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "First Dose",
        "windowLower": -28,
        "windowUpper": -2
      },
      {
        "id": "timing_2",
        "name": "Washout Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 3,
        "relativeTo": "Previous Visit"
      },
      {
        "id": "timing_3",
        "name": "Follow-up Visit",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "Last Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_4",
        "name": "CRU Discharge",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 6,
        "relativeTo": "Last Dose"
      },
      {
        "id": "timing_5",
        "name": "Study Treatment Administration Timing",
        "type": "After",
        "unit": "minutes",
        "instanceType": "Timing",
        "value": 5
      },
      {
        "id": "timing_6",
        "name": "TE ADA Additional Follow-up Sampling",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 84,
        "relativeTo": "Previous Visit",
        "windowLower": -7,
        "windowUpper": 7
      },
      {
        "id": "timing_7",
        "name": "Bedside PG Monitoring Interval (High)",
        "type": "Within",
        "unit": "minutes",
        "instanceType": "Timing",
        "value": 10
      },
      {
        "id": "timing_8",
        "name": "Bedside PG Monitoring Interval (Low)",
        "type": "Within",
        "unit": "minutes",
        "instanceType": "Timing",
        "value": 5
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Admission Rescheduling Condition",
        "instanceType": "Condition",
        "description": "Condition for proceeding with admission to the CRU on Day 1.",
        "text": "Admission can be rescheduled if PG level is not 90 to 250 mg/dL on Day 1."
      },
      {
        "id": "cond_2",
        "name": "Hypoglycemia Induction Endpoint",
        "instanceType": "Condition",
        "description": "Criteria for stopping the insulin infusion.",
        "text": "Insulin infusion is stopped once bedside PG is <60 mg/dL."
      },
      {
        "id": "cond_3",
        "name": "Safety Review Gate",
        "instanceType": "Condition",
        "description": "Condition for continuing enrollment after the first cohort.",
        "text": "Safety data will be reviewed after the first 6 patients are administered LY900018 in Period 2, and the remaining patients will be dosed after confirmation of the safety."
      },
      {
        "id": "cond_4",
        "name": "TE ADA Positive Status",
        "instanceType": "Condition",
        "description": "Condition for entering the additional follow-up period.",
        "text": "Patients with TE ADA at follow-up/ED will undergo additional follow-up."
      },
      {
        "id": "cond_5",
        "name": "Non-inferiority Declaration Criteria",
        "instanceType": "Condition",
        "description": "Statistical condition for declaring the primary objective met.",
        "text": "Non-inferiority of LY900018 will be declared if the upper limit of the 2-sided 95% CI constructed on the difference in percentage (IMG - LY900018) is less than the NIM of 10%."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Screen to Treatment Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_screening",
        "toElementId": "epoch_treatment",
        "text": "Patients who meet all eligibility criteria during the screening period will be enrolled and randomized to a treatment sequence."
      },
      {
        "id": "trans_2",
        "name": "Transition to Additional Follow-up",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_main",
        "toElementId": "epoch_ada_followup",
        "text": "Patients with TE ADA at follow-up/ED will undergo additional follow-up."
      },
      {
        "id": "trans_3",
        "name": "Patient Replacement Rule",
        "instanceType": "TransitionRule",
        "text": "If patients discontinue from the study before completion of both periods with evaluable primary outcome for any reason, the patient may be replaced. Replacement should not occur beyond 75 patients enrolled."
      },
      {
        "id": "trans_4",
        "name": "Continuation of Inadvertently Enrolled Patients",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If a patient who did not meet enrollment criteria was inadvertently enrolled, a discussion must occur between the Lilly CP/CRP and the investigator to determine if the patient may continue in the study."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Discontinuation due to Other Study",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Discontinuation for enrollment in any other clinical study involving an investigational product or other incompatible medical research."
      },
      {
        "id": "exit_2",
        "name": "Investigator Decision to Discontinue",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The investigator decides that the patient should be discontinued from the study for any reason, including an AE, SAE, or a severe hypoglycemia event."
      },
      {
        "id": "exit_3",
        "name": "Patient Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The patient, or legal representative, requests to be withdrawn from the study."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
      },
      {
        "id": "exit_5",
        "name": "Study Discontinuation for Safety",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The study will be stopped if deemed necessary for patient safety following the review of the safety data from the first 6 patients to complete Period 2 Day 1."
      },
      {
        "id": "exit_6",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "Completion of all protocol-required visits, including the follow-up visit 26 to 30 days after the last study treatment."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Admission Decision",
        "timepointId": "pt_period_day1_admission",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point on Day 1 of each treatment period to proceed with or reschedule admission based on plasma glucose levels.",
        "conditionIds": [
          "cond_1"
        ]
      },
      {
        "id": "dec_2",
        "name": "Study Drug Administration Decision",
        "timepointId": "pt_period_day1_hypoglycemia",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point to stop insulin infusion and administer study drug based on achieving the target low plasma glucose level.",
        "conditionIds": [
          "cond_2"
        ]
      },
      {
        "id": "dec_3",
        "name": "Study Continuation Safety Gate",
        "timepointId": "pt_interim_safety_review",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point after the first 6 patients complete Period 2 to determine if the study can continue dosing the remaining patients.",
        "conditionIds": [
          "cond_3"
        ]
      }
    ],
    "summary": {
      "timingCount": 8,
      "conditionCount": 5,
      "transitionRuleCount": 4,
      "exitCount": 6
    }
  }
}